Chair and The Presidential Associate Professor of Family Medicine and Community Health, Department of Family Medicine and Community Health, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.
Senior Research Investigator, Department of Family Medicine and Community Health, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.
CA Cancer J Clin. 2018 May;68(3):199-216. doi: 10.3322/caac.21452. Epub 2018 Mar 30.
Timely follow-up for positive cancer screening results remains suboptimal, and the evidence base to inform decisions on optimizing the timeliness of diagnostic testing is unclear. This systematic review evaluated published studies regarding time to follow-up after a positive screening for breast, cervical, colorectal, and lung cancers. The quality of available evidence was very low or low across cancers, with potential attenuated or reversed associations from confounding by indication in most studies. Overall, evidence suggested that the risk for poorer cancer outcomes rises with longer wait times that vary within and across cancer types, which supports performing diagnostic testing as soon as feasible after the positive result, but evidence for specific time targets is limited. Within these limitations, we provide our opinion on cancer-specific recommendations for times to follow-up and how existing guidelines relate to the current evidence. Thresholds set should consider patient worry, potential for loss to follow-up with prolonged wait times, and available resources. Research is needed to better guide the timeliness of diagnostic follow-up, including considerations for patient preferences and existing barriers, while addressing methodological weaknesses. Research is also needed to identify effective interventions for reducing wait times for diagnostic testing, particularly in underserved or low-resource settings. CA Cancer J Clin 2018;68:199-216. © 2018 American Cancer Society.
及时跟进癌症筛查阳性结果仍不理想,且缺乏有关优化诊断检测及时性的决策依据。本系统评价评估了关于乳腺癌、宫颈癌、结直肠癌和肺癌阳性筛查后随访时间的已发表研究。在所有研究中,由于指示性混杂,大多数研究的可用证据的质量非常低或低,潜在的关联减弱或逆转。总体而言,证据表明,等待时间的延长会增加癌症不良结局的风险,而等待时间在不同癌症类型之间存在差异,这支持在阳性结果后尽快进行诊断性检测,但具体时间目标的证据有限。在这些限制下,我们就特定癌症的随访时间提供了意见,并讨论了现有指南与当前证据的关系。设定的阈值应考虑患者的担忧、随着等待时间延长而失去随访的潜在风险,以及现有资源。需要开展研究以更好地指导诊断性随访的及时性,包括考虑患者的偏好和现有障碍,同时解决方法学上的弱点。还需要开展研究,以确定减少诊断性检测等待时间的有效干预措施,特别是在服务不足或资源有限的环境中。CA Cancer J Clin 2018;68:199-216。© 2018 美国癌症协会。